Dr. Paul Sieber continues his conversation with Dr. Todd Cohen around managing the advanced prostate cancer patient. The use of somatic and germline testing to support decision making within the treatment algorithm are discussed. Medical management changes of positive mutation carriers and the commercial use of PARP inhibitors are also explored.

Managing High Risk Prostate Cancer Pt.2

Myriad Genetics brings you a casual, yet educational podcast about modern topics in Urology. Because every man with prostate cancer deserves a better answer.&nbsp;

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

On this episode of TMU we're diving deep into the rapidly evolving landscape of prostate cancer diagnosis and treatment with special guest, Dr. Adam Cole, a board-certified pathologist. Dr. Cole will discuss the traditional Gleason grading system, the limitations of pathology, and how incorporating genetic markers can improve patient outcomes.  Dr. Cole will touch on the importance of genetic testing in guiding treatment plans, and the potential use of artificial intelligence shaping the future of pathology.

Go Beyond Gleason for Prostate Cancer Treatment Decisions

In this episode of TMU we have the pleasure of being joined by two urology experts, Dr. Ravi Rajan, Urologist, and Dr. William Ding, Radiation Oncologist, as they discuss topics ranging from genetic testing in prostate cancer for personalized treatment plans to the importance of collaboration between urologists and radiation oncologists. Our guests highlight the significance of effective communication and seamless integration within the treatment team. They also  shed light on the consequences of lack of collaboration and how it can impacts patient care and satisfaction. Listen along as they share valuable insights and practical tips for improving communication and collaboration between these specialties.

The Power of Collaboration: Enhancing Patient Care Through Urologist and Radiation Oncologist Partnerships

Join our panel of experts, Dr. Neal Shore, Dr. Ben Lowentritt, Dr. Ted Schaefer, and Dr. Jonathan Tward, as they discuss the various components and utility of a full workup for localized prostate cancer. They explore the importance of germline testing and how it has significant implications for personalized treatment choices. They will also discuss and examine the use of traditional biomarkers like PSA, PSA density, kinetics, and the Gleason grade system, as well as newer advancements in molecular markers and the potential use of artificial intelligence. Tune in as our experts share their insights, experiences, and expectations for the future of prostate cancer care.

Patient Workup at Initial Prostate Cancer Diagnosis

On this episode of TMU, Dr. Mark Edney welcomes Dr. Deepak Kapoor as they dive into the world of private equity and healthcare policy. They discuss the opportunities and challenges faced by private practices in the field of Urology, and explore the topic of private equity with Dr. Kapoor's experiences as the chairman of Solaris Health. Listeners will gain insight into the differences between private equity and venture capital. Dr. Kapoor and Dr. Edney stress the importance of everyone having a voice in this thought-provoking conversation that highlights the ultimate goal of providing great patient care. 

Private Equity in Urology: Opportunities and Challenges

 On this episode of TMU, we sit down with Ray Wezik, the Director of Policy and Advocacy for the American Urological Association (AUA), as we dive into the world of patient advocacy and lobbying. Ray shares his perspective as someone who works with over 75 patient advocacy organizations to leverage their voices and become better advocates together. We discuss the importance of collaboration between patient advocacy and medical professionals for effective efforts, and Ray shares insights on how networking events are bringing patients and urologists to state capitals to advocate for solutions and funding for research programs. Ray also shares valuable insights on working with regulatory agencies like CMS, and the value of determining CPT codes.

Managing High Risk Prostate Cancer Pt.2

Download our free app to listen on your phone